Clostridium butyricum
Selected indexed studies
- Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease. (Gut Microbes, 2021) [PMID:33874858]
- Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. (Cancer Cell, 2025) [PMID:40780216]
- Clostridium butyricum, a future star in sepsis treatment. (Front Cell Infect Microbiol, 2024) [PMID:39711782]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease. (2021) pubmed
- Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. (2025) pubmed
- Clostridium butyricum, a future star in sepsis treatment. (2024) pubmed
- Probiotic Clostridium butyricum ameliorates cognitive impairment in obesity via the microbiota-gut-brain axis. (2024) pubmed
- Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer. (2023) pubmed
- Clostridium butyricum and Its Derived Extracellular Vesicles Modulate Gut Homeostasis and Ameliorate Acute Experimental Colitis. (2022) pubmed
- Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. (2020) pubmed
- Effects of Clostridium butyricum on growth performance, metabonomics and intestinal microbial differences of weaned piglets. (2021) pubmed
- Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer. (2020) pubmed
- Clostridium butyricum and its metabolites regulate macrophage polarization through miR-146a to antagonize gouty arthritis. (2026) pubmed